Jubilant Innovation Pte Ltd

Balance Sheet as at 31 March 2018		USD	INR (' In Thousands)	USD	INR (' In Thousands)
	Notes	As 31 Marc		As 31 Mar	at ch 2017
ASSETS		Or Ivear	2010	On typus	2017
Non-current assets					
Financial assets					
i. Non-current investments	1	480,536	31,317	533,140	34,574
ii. Loans and advances	2	3,994	260	3,994	259
Total non-current assets	· ·	484,530	31,577	537,134	34,833
Current assets					
Financial assets					
i. Cash and cash equivalents	3	943	61	(373)	(24)
Other current assets	4	2,674	174	3,401	220
Total current assets		3,617	235	3,028	196
Total assets	1	488,147	31,812	540,162	35,029
EQUITY AND LIABILITIES					
Equity					
Equity share capital	5	2,922,301	138,091	2,922,301	138,091
Other equity	S=	(2,490,149)	(109,928)	(2,410,226)	(104,883)
Total Equity		432,152	28,163	512,075	33,208
LIABILITIES					
Non-current liability					
Financial liabilities					
 Long-term borrowings 	6	20,000	1,303		2
Total non-current liability	· ·	20,000	1,303		35
Current liabilities					
Financial liabilities					
i. Trade payables	7	35,368	2,305	28,087	1,821
i. Other financial liability	8	627	41		:=:
Total current liabilities	-	35,995	2,346	28,087	1,821
Total liabilities		55,995	3,649	28,087	1,821
Total equity and liabilities	-	488,147	31,812	540,162	35,029

Rajneesh Gupta

Vice President - Finance

Jubilant Innovation Pte Ltd Statement of Profit and Loss for the year ended 31 March 2018

		USD	INR (' In Thousands)	USD	INR (' In Thousands)
	Notes		year ended rch 2018	•	ear ended ch 2017
Revenue from operations		T			
Total income		-	:=:	:**	
Expenses					
Finance cost		627	40	-	=
Other expenses	9	26,692	1,719	19,004	1,275
Total expenses	_	27,319	1,759	19,004	1,275
Loss before tax	-	(27,319)	(1,759)	(19,004)	(1,275)
Tax expense	_				
- Current tax		-	340	:=	=
Total tax expense	-	•		19	
Loss for the year	-	(27,319)	(1,759)	(19,004)	(1,275)
Other comprehensive income					
Exchange differences on translation of foreign					
operations		7.	97	-	(701)
Other comprehensive income for the year, net of tax		le.	97		(701)
Total comprehensive income for the year		(27,319)	(1,662)	(19,004)	(1,976)

Rajneesh Gupta Vice President - Finance

Jubilant Innovation Pte Ltd Statement of changes in equity for the year ended 31 March 2018

		USD
	Reserves and S	urplus
	Retained earnings	Total
As at 1 April 2016	(2,391,222)	(2,391,222)
Loss for the year	(19,004)	(19,004)
Total comprehensive loss for the year	(19,004)	(19,004)
As at 31 March 2017	(2,410,226)	(2,410,226)
Loss for the year	(27,319)	(27,319)
Total comprehensive loss for the year	(27,319)	(27,319)
Investment transferred to holding company	(52,604)	(52,604)
As at 31 March 2018	(2.490.149)	(2,490,149)

Jubilant Innovation Pte Ltd Statement of changes in equity for the year ended 31 March 2018

INR (' In Thousands)

			l housands)
	Reserves and Surplus	Other Comprehensive Income	
	Retained earnings	Foreign currency translation	Total
		reserve	
As at 1 April 2016	(104,955)	2,048	(102,907)
Loss for the year	(1,275)		(1,275)
Exchange differences on translation of		(701)	(701)
foreign operations			
Total comprehensive loss for the year	(1,275)	(701)	(1,976)
As at 31 March 2017	(10/ 220)	1,347	(10.4.992)
	(106,230)	1,547	(104,883)
Loss for the year	(1,759)	07	(1,759)
Exchange differences on translation of foreign operations		97	97
Total comprehensive income/(loss) for	(1,759)	97 -	(1,662)
the year			· · · · ·
Investment transferred to holding	(3,383)		(3,383)
сотрапу			
As at 31 March 2018	(111,372)	1,444 -	(109,928)

Rajneesh Gupta Vice President - Finance

Jubilant Innovation Pte Ltd Statement of Cash Flows for the year ended 31 March 2018

	USD	INR (' In Thousands)	USD	INR (' In Thousands)
		ear ended	_	ear ended
	31 March 2018		31 Ma	rch 2017
A. Cash flow from operating activities				
Loss before tax	(27,319)	(1,759)	(19,004)	(1,275)
Adjustments:				
Finance costs	627	40	-	≦ ≦
Operating cash flow before working capital changes	(26,692)	(1,719)	(19,004)	(1,275)
(Decrease)/ (increase) in trade and other receivables	728	47	(1,022)	(69)
Increase in trade payables, provisions and other liabilities	7,280	470	16,483	1,105
Cash generated from operations	(18,684)	(1,202)	(3,543)	(239)
Net cash (used in) operating activities	(18,684)	(1,202)	(3,543)	(239)
B. Cash flow arising from financing activities				
Proceeds from long-term borrowings	20,000	1,291		-
Net cash generated from financing activities	20,000	1,291		
C. Effect of exchange rate changes	-	(4)	Pa	5
Net increase / (decrease) in cash and cash equivalents (A+B+C)	1,316	85	(3,543)	(234)
Add: cash and cash equivalents at the beginning of year	(373)	(24)	3,170	210
Cash and cash equivalents at the end of the year	943	61	(373)	(24)

Rajneesh Gupta Vice President - Finance

Jubilant Innovation Pte Ltd Notes to the financial statements for the year ended 31 March 2018

Note 1: Non-current Investment

	USD	INR (' In Thousands)	USD	INR (' In Thousands)
	As 31 Mar	at ch 2018	As : 31 Marc	
Non-current Vanthys Pharmaceuticals Development Private Limited (net of provision for impairment) 22,500,000 (31 March 2017: 22,500,000 shares of Rs 10 each)	480,536	31,317	480,536	31,163
Jubilant Drug Discovery and Development Services Inc.Nil (31 March 2017: 50,000 shares of CAD 1each)	100.50	21.215	52,604	3,411
Total non-current investment	480,536	31,317	533,140	34,574

Note: During the current year as part of the Group restructuring, the Company transferred its investment in Jubilant Drug Discovery and Development Services Inc, Canada to its holding Company Drug Discovery and Development Solutions Limited Singapore (DDDSL) w.e.f. 19 September 2017.

Note 2: Loans and advances

Note 2: Loans and advances					
	USD	INR ('In	USD	INR ('In	
		Thousands)		Thousands)	
		As at	As	at	
	= 31 N	farch 2018	31 Man	31 March 2017	
Non-current					
Unsecured, considered good					
Security deposits	3,994	260	3,994	259	
Total loans and advances	3,994	260	3,994	259	
Note 3: Cash and cash equivalents					
•	USD	INR (' In	USD	INR (' In	
		Thousands)		Thousands)	
		As at	As	at	
	31 N	1arch 2018	31 Mar	ch 2017	
Balances with banks	===				
- in current accounts	.943	61	(373)	(24)	
Total cash and cash equivalents	943	61	(373)	(24)	
Note 4: Other current assets					
	USD	INR (' In	USD	INR ('In	
		Thousands)		Thousands)	
		As at	As	at	
	31 N	March 2018	31 Mar	ch 2017	
Prepaid expenses	2,674	174	3,401	220	
Total other current assets	2,674	174	3,401	220	

Jubilant Innovation Pte Ltd Notes to the financial statements for the year ended 31 March 2018

Note 5: Share Capital

Trote 5 , Share Capital	USD	INR (' In Thousands)	USD	INR (' In Thousands)	
	24.3	As at	As at 31 March 2017		
	31 M	March 2018	31 Mar	ch 2017	
Issued, subscribed and paid up					
2,922,301 (31 March 2017: 2,922,301	2,922,301	138,091	2,922,301	138,091	
Equity shares of no par value)					

1). Movement in equity share capital

	Note	No. o	f shares	USD	INR (In thousands)
Balance as at 1 April 2016		5	2,922,301	2,922,301	138,091
Changes in equity share capital during the year			196		-
Balance as at 31 March 2017		5	2,922,301	2,922,301	138,091
Changes in equity share capital during the year			-	#	8
Balance as at 31 March 2018		5	2,922,301	2,922,301	138,091

- 2) The Company has only one class of shares referred to as equity shares having no par value. Each holder of equity shares is entitled to one vote per share. In the event of liquidation of the Company, the holders of equity shares will be entitled to receive any of the remaining assets of the Company after distribution of all preferential amounts, if any, in proportion to their shareholding. However no such preferential amounts exist currently.
- 3) During the current year as part of the Group restructuring, Jubilant Innovation BVI Limited transferred its shareholding in the Company to Drug Discovery and Development Solutions Limited Singapore (DDDSL) becoming the Holding company w.e.f. 22nd November 2017.

4) The details of shareholders holding more than 5% shares in the Company:

-	USD	INR ('In	USD	INR (' In
		Thousands)		Thousands)
	1	As at	As	at
	31 M	arch 2018	31 Mar	ch 2017
,	No of shares	% holding in the	No of shares	% holding in
		class		the class
Name of the Shareholder				
Jubilant Innovation BVI Ltd	14 0		2,922,301	100%
Drug Discovery and Development Solutions Limited	2,922,301	100%		72

Jubilant Innovation Pte Ltd Notes to the financial statements for the year ended 31 March 2018

The second community of the se	USD	INR (' In Thousands)	USD	INR (' In Thousands)
	31 M	As at March 2018	As at 31 March 2	
Non-current				
Loan from related parties	20,000	1,303	175	
Total Long-term borrowings	20,000	1,303	-	

Note 7: Trade payables

	USD	INR (' In Thousands)	USD	INR (' In Thousands)	
	31 1	As at 31 March 2018		As at 31 March 2017	
Current Trade payables	35,368	2,305	28,087	1,821	
Total trade payables	35,368	2,305	28,087	1,821	

Note 8: Other Financial Liability

Note 9. Vener Financial Embility	USD	INR (' In Thousands)	USD	INR (' In Thousands)
	31 N	As at 31 March 2017		
Interest accrued but not due on borrowings - related parties	627	41		
Total other financial liability	627	41		-

Note 9: Other expenses

	USD	INR (' In	USD	INR (' In
Particulars	Thousands)			Thousands)
	For the year ended		For the year ended	
	31 M	March 2018	31 Marc	ch 2017
Auditor's remuneration	6,330	407	5,630	378
Legal and professional fees	17,328	1,116	11,960	802
Bank charges	2,447	158	1,469	99
Subscription	321	21	250	Ces.
Foreign exchange loss/(gain)	266	17	(55)	(4)
Total other expenses	26,692	1,719	19,004	1,275